Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.

In older adults with myeloma who are undergoing treatment with carfilzomib, new cardiac and pulmonary diagnoses were common. Patients with preexisting COPD were found to be at an increased risk of developing CAEs.